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DiagnosticsUnderstanding of cAMP signaling has greatly improved over the past decade. The advent of live cell imaging
techniques andmore speciﬁc pharmacologic modulators has led to an improved understanding of the intricacies
by which cAMP is able to modulate such a wide variety of cellular pathways. It is now appreciated that cAMP is
able to activate multiple effector proteins at distinct areas in the cell leading to the activation of very different
downstream targets. The investigation of signaling proteins in cancer is a common route to the development
of diagnostic tools, prognostic tools, and/or therapeutic targets, and in this reviewwehighlight how investigation
of cAMP signaling microdomains driven by the soluble adenylyl cyclase in different cancers has led to the
development of a novel cancer biomarker. Antibodies directed against the soluble adenylyl cyclase (sAC) are
highly speciﬁc markers for melanoma especially for lentigo maligna melanoma and are being described as
“second generation” cancer diagnostics, which are diagnostics that determine the ‘state’ of a cell and not just
identify the cell type. Due to the wide presence of cAMP signaling pathways in cancer, we predict that further
investigation of both sAC and other cAMP microdomains will lead to additional cancer biomarkers. This article
is part of a Special Issue entitled: The role of soluble adenylyl cyclase in health and disease.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Cyclic adenosinemonophosphate (cAMP) is one of themost ancient
signaling molecules present from bacteria to man. In mammals, cAMP
controls a wide range of cellular processes and is present in every cell
type and organ. cAMP is synthesized from ATP by a class of enzymes
called adenylyl cyclases (ACs), which are encoded by 10 different
genes (ADCY1–10) [1]. ACs 1–9 encode for proteins with a fairly similar
structure in that all of them are transmembrane proteins (tmACs) and
reside principally at the plasma membrane and endosomes making
these ACs well suited to respond to extracellular signals. tmACs provide
an important link between hormonal (e.g., melanocortin stimulating
hormone) signals and intracellular processes. In many ways, tmACse; sAC, Soluble adenylyl cyclase;
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).function to coordinate cells within a tissue. Most tmACs are principally
regulated by G protein coupled receptors via direct stimulation by
heterotrimeric G proteins either by direct interaction between tmACs
and the Gαs subunit or β/γ subunits [1]. Regulation of tmACs can be di-
vided into four groups: Group 1, Ca2+/calmodulin-stimulated AC1, AC3,
and AC8; Group 2, Gα-stimulated and Ca2+-insensitive AC2, AC4, and
AC7; Group 3, Gαi/Ca2+/PKA-inhibited, AC5 and AC6; and Group 4,
forskolin/Ca2+/ Gα-insensitive, AC9 [1]. The more recently identiﬁed
AC (ADCY10) is also called the soluble adenylyl cyclase (sAC), which
unlike the tmACs has no membrane spanning motifs and therefore is
free to localize to multiple locations within a cell of which the best
characterized are the nucleus and mitochondria [2,3]. sAC is primarily
regulated by changes in bicarbonate [4] and calcium ions [5]. Bicarbon-
ate ion functions to both increase the Vmax of the enzyme and alleviate
substrate, ATP, and inhibition [5]. The ability to sense bicarbonate allows
sAC to function as a pH sensor [2,6]. Calcium functions to decrease the
Km for MgATP [5]. Whereas most proteins have a Km for MgATP that
far exceeds the normal resting levels of ATP in the cell, ~1–3 mM
(e.g., tmACs have a Km for MgATP in tens to hundreds of micromolar
[7]), sAC's Km in the presence of calcium is approximately 1–3 mM.
The elevatedKmforMgATPenables sAC to sense changes inmetabolism
[8,9]. In addition to regulation by bicarbonate, calcium and ATP, the sAC
protein contains a P loop [10], a heme binding domain [11] and other
predicted protein domains and phosphorylation sites that may provide
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poised to function as an intrinsic sensor of cellular health.
Since sAC and the nine different tmACs each respond to distinct
signals yet produce the same second messenger, cAMP, it is important
for the cell to respond speciﬁcally to each source of cAMP. The cell has
at its disposal three families of cAMP effector proteins, an entire family
of cAMP catabolizing enzymes, and a family of scaffolding proteins
allowing the cell to establish spatially and temporally separate cAMP
signaling domains (microdomains) capable of inducing a wide variety
of downstream cascades. cAMP microdomains were ﬁrst appreciated
in the 1970s by the groups of Keely, Hayes, Brunton, and others
when they recognized that different tmAC activating hormones
(e.g., β-adrenergic receptor and prostaglandin E1 agonists) all led
to cAMP elevation but each induced unique cellular events in
cardiomyocytes, e.g., only β-adrenergic stimulation induced increased
contractility and glycogen metabolism [12].
In the following sections, wewill review the role of exchange pro-
tein activated by cAMP, protein kinase A, and A kinase anchoring
proteins in cAMP signaling and how investigations of each have
contributed to our understanding of cAMP microdomains. For the
purpose of brevity, we have chosen not to review the vast literature
of cyclic AMP gated ion channels, which lie at the plasma membrane
and are an important link between cAMP signaling and ion transport,
and phosphodiesterases, which catabolize cAMP into AMP and can
be localized to many different areas of the cell. Finally, we will
discuss cAMP signaling in cancer, speciﬁcally melanoma, and how a
better understanding of cAMPmicrodomains in cancer may improve
cancer diagnostics.
2. Exchange protein activated by cAMP
The exchange protein activated by cAMP (EPAC) family of effector
proteins was discovered coincidently by two laboratories in 1998. One
group initiated a database search to determine how cAMP could activate
the small G protein Rap1 in a PKA-independent manner [13] while the
other group found both EPAC1 (cAMP-GEF-I) and EPAC2 (cAMP-GEF-
II) in a differential display screen for novel cAMP binding proteins [14].
Small G proteins cycle between a GDP bound inactive state and a GTP
bound active state. Proteins such as guanine nucleotide exchange
factors (GEFs) facilitate the exchange of GDP for GTP whereas GTPase-
activating proteins (GAPs) help G proteins convert GTP back to GDP.
Because small G proteins have a very slow intrinsic GTPase activity, re-
stricted access to GAPs leads to prolonged activation of the proteins,
explaining why Ras activating mutations block association of Ras with
GAPs. Therefore, proper control of the Rap1 and Rap2 cascades require
both spatial and temporal control over the GEFs and GAPs. EPAC can
have multiple splice variants and is broadly expressed depending on
developmental stage and disease [15]. EPAC1 is highly expressed in
the heart, kidneys, blood vessels, adipose tissue, central nervous system,
ovaries, and uterus [14,16] with multiple hematopoietic cell types.
EPAC2, however, is mostly expressed in the central nervous system,
adrenal gland, and pancreas with no detectable expression in hema-
topoietic cells [17]. EPACs are multidomain proteins with regulatory
domains at the N terminus and the catalytic GEF domain at the C terminus.
Both EPAC genes encode for cAMPbinding domains (cAMP-B domain in
EPAC1 and both cAMP-A and B domains in EPAC2), a disheveled-Egl-
10-pleckstrin (DEP) domain that is responsible for plasma membrane
localization, a Ras exchange motif (REM) domain that assists in cataly-
sis, a Ras association (RA) domain that allows for interaction with GTP
bound G proteins (e.g., Ras), and the CDC25HD domain that provides
GEF activity [17]. Binding of cAMP to the cAMP-A and/or B domains
along with interaction with small G proteins via the RA domain can
alter the location of EPAC proteins and control when and where Rap1
is activated [15,18]. Interestingly, EPAC1 is known to associate with
Ran-GTP, which is thought to control its nuclear localization. Nuclear
EPAC1 is thought to control the DNA damage response and the DNAdamage-responsive DNA-protein kinase [17]. EPAC controls nuclear ex-
port of histone deacetylase (HDAC)-4 and -5 [19,20]. The presence of
EPAC in the nucleus predicts that a source of cAMP should exist to reg-
ulate its activity and/or localization. sAC was shown to localize to the
nucleus in numerous cell types by cellular fractionation and immuno-
histochemistry [3] and later conﬁrmed by FRET based imaging [21].
sAC moves in and out of the nucleus of certain cells during speciﬁc in-
ﬂammatory diseases (e.g., psoriasis), infectious diseases (e.g., human
papillomavirus infection), and malignancy (e.g., squamous cell carcino-
ma andmelanoma) discussed in more detail below [3,22,23]. Since sAC
is known to regulate Rap1 in an EPAC-dependent manner it is plausible
that sAC is a nuclear source of cAMP regulating EPAC in the nucleus.
However, it is important to note that some groups have found that
activation of tmACs can also lead to a rise in nuclear cAMP asmeasured
by a EPAC-FRET probe [21].3. Protein kinase A
Protein kinase A (PKA) is one of the ﬁrst characterized and best
known cAMP effector proteins. It is a broad speciﬁcity serine/threonine
kinase that consists of two catalytic (C) and two regulatory (R) subunits.
This tetrameric holoenzyme is activated when two molecules of cAMP
bind to each R subunit resulting in a conﬁrmational change and release
of active C subunit [24]. There are three C subunits (α, β, and γ). Cα and
Cβ are ubiquitously expressed but Cγ is expressed mainly in the testis
[25]. There are four R subunits which fall into two categories: RI (α
and β) and RII (α and β), and all isoforms are able to bind cAMP. Each
isoform has unique protein domains, which target isoforms to distinct
areas of the cell, and therefore, are subject to different regulation and
downstream substrates [24–26]. Regulatory subunits are not function-
ally redundant. The two major stable and well-folded domains are the
dimerization/docking domain at the N terminus and the two tandem
cAMP binding domains at the C-terminus. The D/D domain is a four-
helix bundle that binds to the amphipathic helix motif characteristic
of A kinase anchoring proteins (AKAPs), which will be discussed in
more depth in the next section [27]. A number of studies have identiﬁed
PKA at distinct locations throughout the cell including themitochondria
[13], the nucleus [28], and the centriole [29], in addition to the plasma
membrane. Localization of PKA is driven by the association of PKA
with AKAPs.4. A kinase anchoring proteins
AKAPs are a large and diverse group of proteins deﬁned by their abil-
ity to bind PKA [25]. There are 43 known genes, which encode the AKAP
family of proteins [30] andmany of these genes producemRNAs that are
alternatively spliced thereby producing N70 distinct AKAP proteins. As
mentioned above, AKAPs are able to bind to the R subunit of PKA via
an amphipathic helix consisting of 14–18 amino acids that bind to the
D/D domain on R subunit [31]. Originally AKAPs were thought to only
bind to RII subunits but it is now accepted that RI subunits can also
bind albeit with much lower afﬁnity [31,32]. AKAPs are found through-
out the cell in many different organelles and associated with different
proteins. This allows AKAPs to tether PKA to different areas of the cell
thereby directing cAMP signaling to speciﬁc targets. While AKAPs are
deﬁned by the ability to bind PKA they can also form multimolecular
signaling complexes, which can include other cAMP signaling proteins
such as PDEs and EPAC, and/or proteins from other signaling cascades
such as MAPK signaling proteins [33]. These AKAP deﬁned microdo-
mains have been well established in cardiac myocytes and the role of
AKAPs in these cells and others has been reviewed previously [33,34];
however, we will illustrate speciﬁc examples of how AKAPs deﬁne
cAMP microdomains to highlight how cAMP can signal in unique
areas of the cell.
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AKAP95 is a nuclear AKAP, which is known to bind the RII subunit of
PKA [35]. It can also bind to cyclin E1 and this interaction is displaced by
cyclin dependent kinases. Interaction of G1/S cyclins can also interact
with RII via AKAP95 suggesting that AKAP95 has a broader effect on
the cell cycle providing a focal point for the interaction between the
cell cycle and cAMP signaling [36]. AKAP95 is associated with the
nuclear matrix during interphase and is found mostly in the chromatin
fraction duringmitosis. Duringmitosis, AKAP95 brings PKA to the chro-
matin and PKA activity is important for the maintenance of condensed
chromatin [37]. AKAP7γ is another nuclear AKAP found in both HEK
293 cells and oocytes and is a dual-speciﬁc AKAP binding both RI and
RII subunits of PKA [38]. It is currently unknown what function is per-
formed by AKAP7γ deﬁned microdomains. Another AKAP, AKAP150,
which binds to RII, is found in the nucleus of precartilidge cells but is
virtually absent from differentiated chondrocytes. This implies that a
nuclear AKAP/PKA microdomain is important for mesenchymal cells
prior to chondrogenesis [39] and highlights how the same cell in differ-
ent stages of growth or differentiation can have different requirements
for nuclear cAMP. The source of cAMP regulating PKA in the nucleus has
been the subject of debate. We and others have demonstrated the
presence of a sAC-dependent cAMPmicrodomain in thenucleus capable
of regulating nuclear PKA [3,40]whereas others have shown that activa-
tion of tmACs leads to a delayed rise of cAMP in the nucleus and PKA
activation [41]. It remains uncertain whether the nuclear rise of cAMP
following tmAC activation at the plasma membrane is due to diffusion
of cAMP from the plasma membrane or the creation of secondary
signaling pathways (e.g., calcium) capable of leading to sAC activation
of PKA in the nucleus.
4.2. AKAPs at the centriole
One of the earliest identiﬁed AKAPswas found localized to the centri-
ole, the cellular structure responsible for organization of microtubules
duringmitosis. Pericentrin is an integral component of the pericentriolar
matrix of the centrosome and is important for centrosome assembly and
organization [42]. PKA RII associates with pericentrin. Another
centrosomal AKAP is AKAP9/450/350/DG-NAP was recently shown to
be part of a multimeric complex consisting of PKA, PDE4D3, and
AKAP9. PDE4D3 regulates a dynamic cAMP microdomain at this AKAP
that changes over the cell cycle [29].
4.3. AKAPs at and in the mitochondria
Mitochondria have been investigated for cAMP microdomains on
the surface and within the organelle. The role of cAMP-dependent sig-
naling cascades, namely those deﬁned by the soluble adenylyl cyclase,
which are present within the mitochondria will not be reviewed here.
In this review,wewill identify a few examples of AKAPs that are present
at and within the mitochondria and how each deﬁnes a distinct cAMP
microdomain within a single organelle. SKIP is an RI-speciﬁc AKAP,
which was shown to localize to the intermembrane space of the
mitochondria and targets PKA to phosphorylate the protein ChChd3, a
protein essential for maintaining cristae integrity [43]. Another
mitochondrial AKAP is Rab32, a member of the Ras superfamily of
small G proteins. Rab32 is a dual function protein both involved in
PKA anchoring and mitochondrial ﬁssion. Proper function of Rab32 is
important formovement ofmitochondria around themicrotubule orga-
nizing center [44]. AKAP121 is a unique mitochondrial AKAP in that it
binds both PKA and steroidogenic acute regulatory protein (STAR)
mRNA, which permits efﬁcient translation and phosphorylation of
STAR protein. AKAP121 is thought to enhance steroidogenesis at the
mitochondria in response to cAMPbydirecting the synthesis and activa-
tion of STAR [45]. AKAP121 has been identiﬁed both outside and on theinner compartment of mitochondria [46]. AKAP121 is important for
cardiac health and its loss leads to the neonatal cardiomyopathy [47].
5. cAMP microdomains in cancer
As we have discussed above, there exist multiple cAMP effector
proteins and cAMP regulatory proteins and these proteins exist in
microdomains throughout the cell. cAMP microdomains can work in
concert [9] or have opposing downstream effects [48]. This can some-
times make the study of cAMP signaling confusing, and this fact is no
better highlighted than in cancer biology. In the next section we will
review some examples of how cAMP signaling can have widely oppos-
ing effects in the deadly skin cancer melanoma. The prototypical cAMP
pathway inmelanoma beginswith the activation of a G protein coupled
receptor such as themelanocortin 1 receptor (MC1R) by thebinding of a
ligand such asmelanocortin stimulating hormone (MSH). MC1R activa-
tion leads to stimulation of tmACs and the generation of cAMP. cAMP
plays an important role in melanocyte biology as a regulator of growth
and pigmentation. Under normal growth conditions, activation of tyro-
sine kinase receptors leads to stimulation of Ras and subsequent activa-
tion of BRAF, MEK, and ERK. While melanocytes contain both BRAF and
CRAF kinases, Ras preferably activates BRAF in normal melanocytes
mainly because CRAF is kept in an inactive state due to phosphorylation
by PKA. Interestingly, and for reasons not completely understood, when
NRAS is mutated in melanoma and becomes activated, the preferred
RAF kinase becomes CRAF [49,50]. This isoform switching is the result
of PDE4 activation and the inhibition of cAMP [51]. These data suggest
that cAMP is an anti-proliferative signal for melanoma and is consistent
with the hypothesis that reactivation of cAMP signaling in NRASmutant
melanomawill induce apoptosis [51]. However, there are also examples
of cAMP elevation having growth promoting effects in melanoma.
BRAFV600E is a common driver mutation for melanoma and while
targeted therapy for this protein exists, resistance soon develops. The
Garrawaygroup recently published an unbiased analysis of cDNAs capa-
ble of rescuing the inhibition of BRAFV600E. Of the 110 cDNAs exam-
ined, many of the proteins capable of rescuing cell death were cAMP
signaling proteins. These data suggest that under these circumstances
cAMP activation promotes melanoma growth. These two examples
highlight how a more complete understanding of cAMP signaling is
needed to better understand melanoma. Furthermore, since melanoma
(regardless of driver mutation) and melanocytes contain the same
cAMP signaling proteins it is reasonable to hypothesize that these dispa-
rate cAMP-dependent effects are driven by distinct microdomains.
The recurrent observation in melanoma and other cancers that
cAMP could play so many seemingly distinct roles prompted us to
examine cAMP microdomains in cancer. We were reminded of earlier
data that sAC driven cAMP microdomains can localize to both the cyto-
plasm, mitochondria and nucleus and that this localization of sAC is
transient [3,22]. We and other investigators have examined whether
sAC is found in distinct localizations in different cancers and whether
these patterns are the same in benign tissue. Since sAC is known to
impact multiple aspects of cellular biology, might a speciﬁc localization
of sAC or change in localization be a helpful marker for clinicians? We
will discuss ongoing studies to address these questions.
6. Use of R21 in the evaluation of the normal epidermis and
keratinocyte proliferations
The laboratory of Drs. Lonny Levin and Jochen Buck developed a
cadre of monoclonal antibodies, which have proven useful for the
study of cAMP microdomains in human tissue [22,28]. We will focus
on one of those antibodies called R21. In the original study of R21 in
human tissue by Zippin et al. [22], cases of normal skin, virally infected
skin, benign and malignant epidermal neoplasia, and inﬂammatory-
mediated epidermal proliferations were stained with themousemono-
clonal antibody against human sAC protein. In normal skin, sAC was
2639G. Desman et al. / Biochimica et Biophysica Acta 1842 (2014) 2636–2645expressed diffusely in the keratinocytes without speciﬁc organellar
localization. Rare keratinocyte nuclear staining was noted. No staining
was identiﬁed in the stratum corneum. Additionally, T-cells, macro-
phages, dendritic cells, eccrine ducts, and cutaneous nerve axons also
expressed sAC. Cases of verruca vulgaris revealed signiﬁcantly reduced
cytoplasmic staining with localization to the nucleus in six of nine
cases. Occasional nuclei lacked staining. In contrast to verruca vulgaris,
all seven cases of molluscum contagiosum lacked nuclear staining and
instead exhibited granular cytoplasmic and perinuclear staining
thought to be mitochondrial. Interestingly, high grade squamous
dysplasia (i.e. bowenoid papulosis) associated with high-risk strains of
HPV (types 16, 18, 31, and 33) lacked nuclear expression and instead
demonstrated perinuclear granular staining. Seborrheic keratoses,
actinic keratoses, and UV-associated squamous cell carcinoma in situ
exhibited predominantly nuclear sAC staining with decreased cytoplas-
mic staining compared to normal epidermis. Interestingly, approxi-
mately 50% of invasive squamous cell carcinomas exhibited nuclear
localization of sAC within the in situ component, but lost nuclear ex-
pression in the invasive component. In fact, in some of these invasive
foci, there was complete loss of sAC staining. Comparedwith squamous
cell carcinoma, basal cell carcinomas demonstrated a very different sAC
immunostaining pattern in which intense cytoplasmic staining and no
nuclear staining was identiﬁed. In inﬂammatory lesions, sAC localized
to the nucleus in all forms of psoriasis, whereas in pityriasis rubra pilaris
the stainingwas predominantly cytoplasmic with little to no increase in
nuclear staining. Nuclear staining was further investigated in vitro in
the cell line MDCK. It was established that sAC was present in the
nucleus of actively dividing cells but was excluded from the nucleus in
differentiated cells [22].
The observation that sAC staining is different between benign and
malignant keratinocytes prompted the investigation of other cell types
and cancers namely melanoma. Because of the difﬁculty in diagnosing
melanoma and the severity of the disease, the application of sAC anti-
bodies to the evaluation of pigmented lesions has become an area of
active research. To properly appreciate how investigation of cAMP
microdomains has added to the diagnosis of cancer, we will ﬁrst review
the current state of melanoma diagnostics and then focus on the data
supporting the use of anti-sAC antibodies in the diagnosis of melanoma.
7. Current state of melanoma diagnostics
Malignantmelanoma is among themost aggressive of humanmalig-
nancies, with incidence rising 3–5% per year in the young and elderly
populations. As its incidence continues to rise, it is estimated that by
2015, one in 50 Americans will developmelanoma during their lifetime
[52]. Accurate and early diagnosis is crucial for prevention of disease
spread, and is a signiﬁcant factor in determining survival.
7.1. Diagnostic interpretation of melanocytic proliferations
Routine light microscopy in which architectural and cytologic fea-
tures are independently assessed to formulate a prediction of biological
behavior remains the gold standard for distinguishing benign and
malignant melanocytic proliferations [53]. In benign melanocytic nevi,
rounded nevomelanocytes proliferate along the dermal epidermal junc-
tion formingnests at the tips of the rete ridges termed a junctional nevus.
Melanocytes may also be present in the dermis but exhibit so-called
maturation with descent, where the cells become smaller and more
neuroidal in morphology thereby forming a compound nevus. Dermal
mitoses should not be present. Cases in which all of the nevus cells
are conﬁned to the dermis and maintain maturation with descent
are intradermal nevi. Cytologically, these intraepidermal and dermal
nevomelanocytes lack signiﬁcant pleomorphism with small round
nuclei and inconspicuous nucleoli. Loss of melanocyte cohesion and up-
ward scatter into the epidermis combined with areas of conﬂuent
growth are features consistent with superﬁcial spreading melanomain situ. Nests ofmelanocytesmay be seen inﬁltrating the dermis in inva-
sivemelanomawhere themelanocytes reveal little evidence of matura-
tionwith descent and occasional mitoses. Thesemalignantmelanocytes
are typically large and pleomorphic with prominent nucleoli. The dys-
plastic nevus is amelanocytic proliferation characterized by a junctional
melanocytic component that extends laterally beyond the dermal
component (so-called “shoulder”), fused rete ridges via nests of
nevomelanocytes, and drape-like ﬁbroplasia within the papillary
dermis. The fusion of the rete ridges by nevomelanocytes may focally
demonstrate conﬂuent melanocytic growth and occasional rare
melanocytesmay be seen above the basal layer. Additionally, the lateral
junctional “shoulder” of melanocytic nests may result in lesional
asymmetry, which may signify additional mutations and evolution to
melanoma. Many dermatopathologists believe these lesions pose a
risk for biological instability and therefore a grade of cytologic atypia
is reported along with the diagnosis [54]. Unfortunately, the unequivo-
cal distinction between benign nevus and malignant melanoma cannot
be made in some cases, in which case re-excision is performed.
7.2. Immunohistochemical (IHC) stains in the diagnosis of melanoma
With the rapid evolution of thismalignancy, there is a great need for
improving diagnostic techniques and IHC evaluation is the mainstay of
adjunctive diagnostic techniques.Melanomahas awide variety of histo-
pathological presentations, making it difﬁcult to rely on pathological
features alone to make an accurate diagnosis. In addition, metastatic
melanoma can be found anywhere in the body and can present with a
myriad of signs and symptoms. Thus, while conventional histology is
the gold standard for diagnosis of melanoma, it often fails to accurately
distinguish benign frommalignant melanocytic lesions and to correctly
identify metastatic melanocytic lesions. IHC studies are frequently
utilized to aid in the diagnosis of melanoma, particularly melanocytic
differentiation and proliferation markers. However, while our current
armamentarium of IHC markers is able to differentiate melanocytic
from non-melanocytic lesions, they are less apt at distinguishing
dysplastic nevi frommalignant neoplasms. Identiﬁcation of new immu-
nohistochemicalmarkers would greatly expand the diagnostic efforts of
clinicians and dermatopathologists and improve survival among
patients with melanoma.
7.3. Melanocyte identiﬁcation markers
Among the myriad of IHC markers identiﬁed, melanocytic markers
have been successfully utilized in the distinction of melanocytic tumors
from non-melanocytic histologic mimics. Of these markers, S-100 re-
mains one of the oldest and most frequently used melanocytic markers
in clinical practice. Originally extracted from a protein fraction in bovine
brain tissue in 1965, S-100 is a calcium-binding protein soluble in 100%
saturated ammonium sulfate [55]. The S-100 protein family has greater
than 25 members and is encoded by several genes many of which are
located on the “epidermal differentiation cluster” in 1q21. This area is
frequently rearranged in many tumors, including melanoma [56].
S-100 proteins are multifunctional, participating in a variety of cellular
processes including cell growth and differentiation, cell cycle progres-
sion, structural membrane organization, transcription, motility, protein
phosphorylation and protection from oxidative cell damage [57]. These
proteins have been identiﬁed in Schwann cells, astrocytes, oligodendro-
cytes, adrenal medulla, chondrocytes, adipocytes, myoepithelial cells
and melanocytes [58].
Expressed in more than 95% of primary cutaneous melanomas,
S-100 is the most sensitive marker for melanocytic lesions, with sensi-
tivity reported from 88% to 100% [56,59]. It is particularly helpful in
assessing metastatic melanoma, where expression of other melanocyte
speciﬁc antigens may be lost (i.e. Melan-A, MITF). In addition, S-100 is
one of the few immunohistochemical markers to identify spindle cell
melanomas, though 10% of desmoplastic melanomas have weak or no
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monoclonal or polyclonal antibodies that react strongly with S-100B
primarily, and weakly with S-100A1 or S-100A6 [61]. The characteristic
pattern of S-100 in melanoma is strong and diffuse staining in both the
nucleus and cytoplasm, with some areas of focal staining as well [62].
While S-100 is a frontrunner in sensitivity, the abundant and varied ex-
pression of this protein limits its speciﬁcity for identifying malignant
melanocytic lesions, reported at 70–87% [63,64]. S-100 even reacts
with certain epithelial neoplasms, including mammary carcinoma and
other carcinomas of the salivary glands, sarcomas and Langerhans cell
histiocytosis. Therefore, while S-100 remains a useful immunohisto-
chemical marker for melanocyte identiﬁcation, its use is limited when
distinguishing between benign and malignant lesions.
HMB (human melanoma black) 45 is another useful marker of mela-
nocyte identiﬁcationused in thehistopathological diagnosis ofmelanoma.
This marker identiﬁes the cytoplasmic premelanosomal glycoprotein
gp100 (PMEL17, SILV, ME20, D12S53E), a type 1 membrane-bound
melanosomal protein product of the SILV gene, which plays an impor-
tant role in the structural organization of melanosomes [65]. HMB45 is
a monoclonal antibody raised against the whole cell extract of the
pigmented melanoma cell line Mel-1, derived from a lymph node in-
volved in metastasis [66]. The HMB immunogen reacts with cutaneous
fetal melanocytes and prenatal, infantile retinal pigmented epithelium,
but does not react with adult normal melanocytes [65]. HMB45 stains
junctional nevi and the junctional component of compound nevi, but
does not stain intradermal nevi and the deep component of compound
nevi [67]. Numerous studies have reported HMB45 sensitivity as
69–95% and speciﬁcity of up to 100% for diagnosis ofmelanoma; howev-
er, HMB45 is known to be less sensitive in metastatic melanoma [61,68,
69]. Thus, this marker can be helpful in distinguishing primary
cutaneous melanoma from some nevi, especially in conjunction with
the proliferation marker Ki67 [70].
HMB45has a distinct cytoplasmic staining pattern inmelanocytic le-
sions [71]. In benign nevi, HMB45 labeling is strongest at the upper
portion of the lesion, but is decreased, with limited or no signal in the
deeper dermis; in contrast, in primary cutaneous melanoma, HMB-45
staining is patchy in both the superﬁcial and deep portions of the lesion
[70]. Due to the patchy staining in intraepidermal melanocytes, studies
have noted that HMB45 often underestimates melanocyte density in
these lesions, and fails to detect all desmoplastic and many amelanotic
melanomas, posing potential diagnostic problems with this marker
[67]. Aside frommelanocytic lesions, HMB45 also reacts with PEComas,
clear cell sarcomas, pigmented neuroectodermal tumors, ovarian
steroid cell tumors and renal cell sarcomas with t(6;11)(p21;q12)
translocations, as well as some breast and sweat gland tumors [61].
HMB45 is therefore useful in the diagnosis of some cutaneous melano-
mas, but has some drawbacks.
Another useful marker of melanocyte identiﬁcation is Melan-A, a
product of the MART-1 gene located on chromosome 9p24.1 [63].
Melan-A is a transmembrane protein cloned from the melanoma cell
line SK-Mel29 that is recognized by autologous cytotoxic T-cells [72].
The protein plays a role in stability, expression and trafﬁcking of the
protein PMEL17, and is important in the formation of stage II melano-
somes [64]. Melan-A is expressed in the cytoplasm of mature melano-
cytes of the skin and retina and is localized to the melanosomes and
endoplasmic reticulum. The overall sensitivity of Melan-A is 85–95% in
primary melanoma and 57–92% in metastatic melanomas [73,74].
Two mouse monoclonal Abs were created to identify Melan-A is tis-
sue. M2-7C10 was produced by Kawakami et al. at the National Cancer
institute, and A103 was produced by Chen et al. at the Ludwig institute
[63,72]. Aside frommelanomas, these antibodies stain junctional, intra-
dermal, compound, congenital, Spitz and dysplastic nevi limiting its
speciﬁcity [64]. Interestingly, Melan-A stains the dermal component of
nevi homogenously, while other markers such as HMB45 and PNL2
stain the dermal–epidermal and superﬁcial junction of melanocytes
[70]. To its disadvantage, Melan-A stains pigmented keratinocytes, andfalsely labels pseudomelanocytic nests in the setting of a lichenoid inﬁl-
trate, further limiting its speciﬁcity [65]. Furthermore, this protein is not
typically expressed in desmoplastic melanomas. Aside from
melanocytic lesions, Melan-A reacts with PEComas, some clear cell sar-
comas, some adrenal cortical and gonad steroid tumors (A103) [75].
One signiﬁcant advantage of Melan-A over other markers is its lack of
expression in dendritic cells in lymph nodes. This feature makes
Melan-A a useful marker in detection of micrometastasis in sentinel
lymph nodes, superior to S100, which does stain dendritic cells [73].
Melan-A is another useful marker of melanocyte identiﬁcation, and
when positively expressed, is helpful in establishing a diagnosis of pri-
mary cutaneous and metastatic melanoma.
Microphthalmia transcription factor (MITF) is a bHLH-Zip dimeric
transcription factor encoded by the MITF gene on chromosome
3p14.1. MITF exists in 10 isoforms, of which MITF-M is selectively
expressed inmelanocytes and regulates transcription of genes formela-
nogenesis, cell survival and differentiation [69]. A monoclonal antibody
to MITF, D5, is used to detect the nuclear pattern of protein expression
in tissues. This nuclear staining greatly facilitates diagnosis in cases of
suspected melanoma with cytoplasmic pigment. MITF is expressed in
melanoma as well in as all common, acquired, dysplastic, blue and
Spitz nevi [69]. In numerous studies, MITF has a reported sensitivity
of 81–100%, with a speciﬁcity of 88–100% for malignant melanoma
[62,70,74]. Signiﬁcantly lower sensitivity is reported in desmoplastic
lesions, ranging from 0 to 55% [69,76]. MITF can be particularly
challenging in suspected cases of desmoplastic melanoma, as it stains
mesenchymal and neural spindle cell neoplasms, as well as Schwann
cells and stromal ﬁbroblasts [69]. Other non-melanocytic lesions,
including angiomyolipomas, clear cell sarcomas, lymphangiomas
and reports of carcinomas of the pancreas, kidney, breast and ovary
express MITF, decreasing the speciﬁcity of this marker for melanoma
[74].
A newer immunohistochemical marker, PNL2, has been less
frequently used in the diagnosis of melanocytic lesions. PNL2 is a
monoclonal antibody generated against a subtype of the human so-
matostatin receptor SST2. While the speciﬁc antigen is unknown,
the protein likely plays a role in melanin pigment synthesis or stor-
age [70]. PNL2 is expressed in melanocytes and neutrophils, staining
benign nevi and primary malignant melanoma, Spitz, dysplastic and
blue nevi. In compound nevi, staining is most prominent at the der-
mal–epidermal junction and superﬁcial dermis, whereas the deep
dermal component is often negative or very weakly positive [70,
71]. PNL2 reportedly stains 80% of spindle cell melanomas, but does
not stain desmoplastic melanomas or other non-melanocytic soft
tissue neoplasms, with the exception of the pigmented component
of melanotic schwanomas and PEComas [70]. This melanocytic
marker has a reported sensitivity similar to that of Melan-A, MITF
and Tyrosinase at 89%, but was found to recognize some S100-
negative metastatic melanomas, making it potentially useful as an
adjunct to S100 in immunohistochemical studies [71].
KBA62 is another newer melanocytic marker raised to the KAL mela-
noma cell line. Thismarker recognizes an unknown antigen expressed in
melanoma cell lines and in malignant melanoma and some carcinomas
[71]. Unlike other melanocytic markers, KBA62 also detects pericytes
and stains vascular and visceral smooth muscle, breast myoepithelial,
epidermal basal and stromal cells, as well as the glomerular basement
membrane, hair shaft of the epithelia of skin, astrocytes, and cells of
the uterine exocervix and tonsils [77]. In melanocytic lesions, KBA62 re-
acts with all histopathologic subtypes of nevi, staining the deep dermal
component of compound nevi, unlike PNL2, which does not stain the
deeper dermal area [70]. KBA62 identiﬁed primary, metastatic and
desmoplastic melanoma with 93%, 86–91% and 82–100% sensitivity,
respectively [70,71].
Similar to Melan-A, KBA62 does not react with dendritic cells in
lymph nodes, making it a helpful marker in investigated sentinel
lymph node metastasis [73]. Non-melanocytic lesions including clear
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mesynchymal neoplasms have shown to be reactive, while PEComas
are usually negative [71].
7.4. Melanocyte proliferation markers
While melanocytic identiﬁcation markers distinguish melanocytic
lesions from non-melanocytic neoplasms, proliferation markers at-
tempt to separate malignant lesions from their benign counterparts.
Of the proliferation markers studied, Ki67 is the most widely used by
dermatopathologists. Ki67, detected by the monoclonal antibody
MIB-1, is expressed in the nuclei during G1, M, G2 and S phase of the
cell cycle, but is absent in G0 and resting cells [78]. Studies have
shown little to no staining in common benign nevi, but signiﬁcantly
increased staining in primary and metastatic melanomas [79]. Patterns
of expression in melanocytic lesions reﬂect cellular maturation; while
common and dysplastic nevi show immunoreactivity in less than 1%
of cells, speciﬁcally at the dermal–epidermal junction or superﬁcial
dermis, melanomas show diffuse, random reactivity in more than 10%
of cells [59]. A similar pattern is identiﬁed when using HMB45 to
investigate a melanocytic lesion [59]. Furthermore, staining patterns in
malignant neoplasms suggest that proliferative activity may be related
to degree of malignancy, as higher levels of MIB-1 expression have
been identiﬁed in metastatic melanomas [78,80]. Proliferation index
seems to correlate with prognostic parameters such as Breslow thick-
ness, nuclear size and tumor stage as well [81]. Ki67, in conjunction
with melanocytic identiﬁcation markers (i.e. Melan-A/Ki67 costaining),
is an important immunohistochemical marker for the diagnosis of pri-
mary cutaneous and metastatic melanoma. When the stain is used
alone, it frequently labels tumor inﬁltrating lymphocytes, which may
result in false positive interpretation.
Another proliferation marker currently under investigation is prolif-
eration cell nuclear antigen (PCNA). PCNA is a polymerase accessory
protein that is present throughout the cell cycle, most signiﬁcantly in
the late G1/S phase, and functions as a cofactor of DNA polymerase
delta [82]. As a nuclear stain, PCNA has demonstrated the highest
staining intensity in metastatic malignant melanoma. Studies have
thus suggested that this protein may be correlated with tumor grade
[83].
A major problem with the interpretation of melanocytic lesions is
the lack of diagnostic reproducibility among dermatopathologists [84].
The battery of stains most frequently used are those that highlight the
location and density of melanocytes within the epidermis. Melan-A
(MART-1) andMITF aremelanocyte speciﬁc markers that stainmelano-
cyte cytoplasm and nuclei, respectively [73]. While these markers are
extremely helpful in highlighting the architectural features of the
melanocytic proliferation, they provide no information regarding the
cytology or biological nature of the melanocytes in question. Therefore,
a marker which highlights the biological signiﬁcance of melanocytic
proliferations would be helpful.
8. Role of R21 (sAC) immunohistochemistry in
melanocytic proliferations
sAC immunohistochemical staining of various benign andmalignant
melanocytic lesions using the R21 antibody revealed distinct patterns
of sAC expression [85]. While all anti-sAC monoclonal antibodies
were evaluated R21 had the best efﬁcacy as it relates to melanocytic
proliferations.
8.1. Normal melanocytes and benign nevi
Normal intraepidermalmelanocytes stainedwith R21 demonstrated
a discrete perinuclear dotlike pattern of staining. Similarly, melanocytes
present in benign melanocytic growths such as lentigo simplex, solar
lentigo, and chronic photoactivation exhibited the identical pattern ofstaining as normal melanocytes. Benign congenital and common
acquired nevi without morphological features of dysplasia and nevi of
special sites also demonstrated this discrete perinuclear dotlike staining
pattern. Although rare isolated granular nuclear and nucleolar staining
may occasionally be seen, the staining intensities are similar to those
of the background keratinocytes. Rare isolated melanocytes with
pannuclear staining may be identiﬁed in a minority of cases of benign
nevi.
8.2. Superﬁcial spreading melanoma
In superﬁcial spreading melanomas, pannuclear staining for R21 is
seen in 25–100% of malignant melanocytes [85]. There appears to be
increased variability in the types of staining patterns seen within the
malignant melanocyte population of any given tumor of this type.
Some malignant melanocytes exhibit a broad perinuclear pattern of
staining, some malignant melanocytes lack nuclear staining altogether,
and others may demonstrate nucleolar staining. Small perinuclear
dotlike staining is seen in less than 10% of cases. Melanomas arising
within preexisting nevi have been shown to demonstrate pannuclear
staining, whereas the benign nevus cells demonstrate perinuclear
dotlike staining. Although the presence of pannuclear staining in greater
than 25% of melanocytes appears to provide high speciﬁcity for estab-
lishing a diagnosis of melanoma, larger studies evaluating atypical
melanocytic nevi and superﬁcial spreading typemelanomas are needed
to better assess sensitivity.
8.3. Nodular melanomas
Nodular melanomas exhibit pannuclear staining, but in fewer cells
compared with other melanoma subtypes [85]. The remaining cells ex-
hibit either ill-deﬁned “granular” nuclear staining or nucleolar staining.
Intense and diffuse cytoplasmic staining of R21 in nodular melanomas
appears to be a unique feature. Although diffuse cytoplasmic staining
may be seen in other forms of melanoma, the staining in nodular
melanoma is both quantitatively and qualitatively greater. Discrete
perinuclear dotlike staining is typically lost. Additional larger studies
are needed to conﬁrm if this pattern of staining is useful as a diagnostic
adjunct in diagnosing these tumors.
8.4. Metastatic melanoma and capsular nevus
Metastatic melanomas with a spindle cell morphology exhibit a
pannuclear staining pattern for R21, but lesions with an epithelioid
morphology exhibit various patterns of staining including pannuclear,
loss of perinuclear dotlike staining, intense diffuse cytoplasmic staining,
and no staining [7]. When assessing lymph nodes for melanoma
metastasis, it is not uncommon to ﬁnd small clusters of banal
nevomelanocytes within the lymph node capsule. These foci are re-
ferred to as capsular nevi. On rare occasion, the distinction of benign
nevus from metastatic melanoma may be difﬁcult due to cytologic
atypia. These benign capsular nevi exhibit a weak cytoplasmic or
perinuclear dotlike pattern of staining with R21 [85].
8.5. Lentiginous malignant melanomas
Lentiginous melanocytic proliferations are another type of
melanocytic lesion characterized by proliferating melanocytes along
the dermal epidermal junction in a solitary linear fashion of varying den-
sities. Benign lentigo simplex and solar lentigo represent the benign end
of the spectrumwhere themelanocytes are of low density, small in size,
and contain inconspicuous nucleoli. In situ mucosal melanoma, acral
lentiginousmelanoma, and lentigomaligna are characterized by conﬂu-
ent, “back-to-back,” single ﬁle growth of melanocytes along the basal
layer. These malignant lesions contain melanocytes that exhibit pleo-
morphism, enlarged nuclei, and prominent nucleoli. In some cases of
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layer may only focally approach conﬂuence and the cytologic features
may be abnormal but equivocal for malignancy [86]. These cases that
do not fulﬁll the full criteria for lentigomaligna are referred to as chronic
photoactivation ofmelanocytes and are another frequent source of diag-
nostic difﬁculty. Since lentigomalignamelanomas arise in a background
of chronic UV exposure, the determination of where melanoma stops
and chronic photoactivation begins is extraordinarily difﬁcult even
with adjunct melanocyte speciﬁc immunohistochemical markers (i.e.
Melan-A, HMB45, and MITF). In acral lentiginous and lentigo maligna
melanomas an R21 pannuclear staining pattern with greater intensity
than the surrounding keratinocytes is seen consistently. Within any
given case, the percentage of malignant melanocytes with pannuclear
sAC expression is greater than 90% of the total tumor cell population
(Fig. 1). In acral lentiginous melanoma, and to a lesser extent lentigo
maligna, a superimposed thick broad perinuclear staining pattern
may be occasionally seen in random tumor cells, however a discrete
perinuclear dotlike pattern without intense nuclear staining is absent.
A recent study has investigated the use of R21 immunohistochemcial
staining in evaluating margins of lentigo melanoma melanoma [23].
The authors propose that a diluted methodology for R21 immunostain-
ing results in less keratinocyte stainingwith preserved pannuclear stain-
ing of melanoma cells. At this dilution, the perinuclear dotlike pattern isFig. 1. Comparison of IHC markers in lentigo maligna. A) Hematoxylin and eosin staining
of lentigo maligna showing multiple atypical melanocytes along the dermal–epidermal
junction and large atypical nests (40×). B) Melan-A in brown stain (40×) and
C) HMB45 in brown stain showing a conﬂuent staining of melanocytes (20×). D) R21
(sAC) in red stain with a pannuclear localization (40×). Human tissue samples were for-
malin ﬁxed and parafﬁn embedded followed by antigen retrieval and immunohistochem-
istry as described in [23].faint or absent. Therefore, the authors propose that the presence or ab-
sence of pannuclear staining results in a more simpliﬁed interpretation.
When assessing lentigomalignamargins they concluded thatmore than
nine R21 pannuclear staining melanocytes within one high-power
ﬁeld and/or a R21 to Melan-A ratio greater than 0.5 are associated
with a positive margin. Conversely, ﬁve or less R21 pannuclear staining
melanocytes per high-power ﬁeld and/or a R21 to Melan-A ratio less
than 0.3 was associated with a negative margin. As a comparison, non-
melanoma skin cancer re-excisions showed a faint benign perinuclear
dotlike staining pattern within melanocytes, consistent with the notion
that pannuclear staining with R21 is a feature of lentigo melanoma cells
only [23]. This algorithmic approach with R21 immunostaining was
recently applied to the technique of slow Mohs for lentigo maligna
melanoma. In this paper the authors compared R21 to MITF for the
semi-rapid assessment of lentigo maligna margins and found R21 to
be more speciﬁc than MITF [87]. Recent work from our group suggests
that R21 could be applied to Mohs frozen sections for the rapid surgical
clearance of lentigo maligna at the bedside (Drs. Desman and Minkis,
pers. comm.).
8.6. Melanocytic lesions associated with ﬁbrosis
The histopathologic interpretation ofmelanocytic lesionswithin areas
of ﬁbrosis can be diagnostically challenging for the dermatopatholgist
due to the disruption of the architecture in which the melanocytes col-
onize the epidermis and dermis [88]. Additionally, the melanocytes
overlying various ﬁbrosing dermal proliferations, such as scar beds,
can exhibit varying degrees of cytologic atypia presumably attributed
to regional growth factor and cytokine milieus. Common causes for
these phenomena include chronic irritation/superﬁcial trauma, prior bi-
opsy, and regression. Intraepidermal melanocytes overlying ﬁbrous
papules may exhibit an increased density with signiﬁcant cytologic
atypia and thus mimick lentigo maligna melanoma when superﬁcially
sampled [89]. Lastly, genital nevi with superimposed changes of lichen
sclerosus may exhibit severe architectural distortion mimicking mela-
noma.While immunohistochemical staining for Melan-Amay be useful
in highlighting the distorted architecture, such as conﬂuent growth and
pagetoid ascent, it does not provide any information regarding the bio-
logical behavior of these cells. As previously mentioned, HMB45 is pos-
itive in junctional and papillary dermal nevus cells as well as stimulated
normal melanocytes overlying scar beds and in areas of chronic
photoactivation, and is therefore not useful in distinguishing benignan-
cy frommalignancy in these situations. InMagro et al. [85], R21was ex-
amined in recurrent/residual nevi and found to have a preserved
perinuclear dotlike staining in the areaswhere themelanocytes demon-
strated enhanced architectural and cytologic atypia in zones of cicatrix.
Likewise, in the study by Magro et al. where a diluted methodology for
R21 staining was applied to re-excision specimens of reactive
lentiginous melanocytic hyperplasia and lentigo maligna, pannuclear
staining was not reported in the hyperplasia cases associated with cica-
trix but was present in the cases of lentigo maligna [85]. A recently re-
ported case of genital nevus arising in the background of lichen
sclerosus in a 7-year-old female presented with markedly atypical ar-
chitectural and cytologic features, but was conﬁrmed benign after the
absence of cytogenetic abnormalities by Fluorescence in situ hybridiza-
tion (FISH) assay for RREB1 (6p25), MYB (6q23), CCND1 (11q13) genes,
and centromere 6. Immunohistochemical staining with R21 revealed a
perinuclear dotlike pattern of staining without pannuclear staining
[90]. Recently, the expression of HMB45 and R21 were compared in be-
nign lentiginous melanocytic hyperplasias overlying ﬁbrous papules in
which varying densities and degrees of cytologic atypia are frequently
encountered. While lesions sampled at the base rarely pose diagnostic
difﬁculty, superﬁcially sampled lesions with little dermis can be indis-
tinguishable from lentigo maligna. We now report a study of six cases
of ﬁbrous papule with overlying benign lentiginousmelanocytic hyper-
plasia and three cases of lentigomalignamelanomaas a positive control.
Fig. 2. R21 has a benign staining pattern in melanocytic lesions overlying a cicatrix.
A) Hematoxylin and eosin staining of ﬁbrous papule revealing an increased density of en-
larged basal layer melanocytes (40×). B) Melan-A, brown stain, reveals increased density
of melanocytes approaching conﬂuence (20×). C) HMB45, brown stain, reveals increased
density of melanocytes with rare cells above the basal layer in an area of irritation (20×).
D) R21 (sAC), red stain, reveals perinuclear dot (benign) staining in melanocytes (40×).
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lanocytes with Melan-A, positive immunoreactivity for HMB45, and a
pan-nuclear staining pattern with R21 (Fig. 1a–d). In comparison, all
six ﬁbrous papule cases exhibited a lentiginousmelanocytic hyperplasia
along the basal layer with melanocytes exhibiting an enlarged epitheli-
oid appearance with retraction artifact and enlarged nuclei (Fig. 2a).
Characteristic stromal features of ﬁbrous papule were present in the
dermis of all cases. The Melan-A stain revealed an increased density of
dendritic melanocytes along the dermal epidermal junction with focal
areas of conﬂuent growth. In irritated lesions, it was not uncommon
to see rare melanocytes above the basal layer (Fig. 2b). All cases stained
with HMB45 revealed positivity within the melanocytes (Fig. 2c). The
R21 immunostaining revealed absent pannuclear andweak perinuclear
dot staining in all cases (Fig. 2d). Therefore, in superﬁcially sampled
melanocytic hyperplasias overlying ﬁbrous papule lesions or cicatrixwhere the histological differential diagnosis includes lentigo maligna,
theR21 expression proﬁle is promising as a diagnostic adjunct for differ-
entiating benign from malignant melanocytic hyperplasias.
In summary, the R21 antibody has proven a useful adjunct in the as-
sessment of pigmented lesions. Benign melanocytes have a reproduc-
ible golgi staining pattern whereas bona ﬁde malignant melanocytes
demonstrate a predominance of pan-nuclear staining. The pan-nuclear
R21 immunostaining pattern is only present in malignant melanocytes
making this pattern highly speciﬁc for melanoma.While some subtypes
of melanoma have pan-nuclear staining in nearly all the melanocytes
(lentiginous growthmelanomas), other subtypes (superﬁcial spreading
melanoma) may have a limited number of pan-nuclear positive cells.
Therefore, depending on the subtype of melanoma, the R21 immuno-
staining pattern has a variable sensitivity for the diagnosis ofmelanoma.
Because of the stark difference in staining pattern between benign
and malignant melanocytes, our group and others are actively investi-
gating whether R21 immunstaining is useful in establishing incipient
melanoma.
9. Conclusion
It has become evident that cAMP signaling can occur in multiple
distinct microdomains throughout the cell, which are initiated by both
tmACs and sAC and are facilitated by multiple effector and regulatory
proteins. In diseases such as cancer, the effects of cAMP signaling path-
ways can sometimes present conﬂicting outcomes, which most likely
result from the presence of multiple cAMP microdomains in those
cells. The use of global cAMP activatingdrugs such asmembrane perme-
able cAMP analogs, forskolin, and pan-speciﬁc PDE inhibitors make sep-
arating each of these cAMPmicrodomains difﬁcult. The challenge going
forward will be the development of sensitive live cell monitoring tech-
niques and more speciﬁc, physiologically relevant tools for changing
cAMP level in living cells. Investigation of cAMP signaling in melanoma
suggests that there are two sets of cAMP dependent pathways: one that
leads to cell growth and one that is inhibitory. sAC is known to change
localization when cells transition from a differentiated state to a prolif-
erative state and as detailed in this review, we and others have been
able to leverage this observation to improve the diagnostic assessment
of melanoma. sAC nuclear localization is a strong indicator of malignant
transformation of melanocytes. Furthermore, sAC staining provides a
high level of speciﬁcity for the diagnosis of melanoma, especially in
lentigo maligna melanoma, a unique quality among melanoma IHC
markers. In addition, sAC staininghas the potential to aid in the rapid as-
sessment of lentiginous growth melanoma margins during MOHs sur-
gery and the difﬁcult assessment of melanocytic lesions overlying
cicatrix, a frequent diagnostic conundrums. It is still unknown whether
the presence of sAC in the nucleus or the percentage of cells with sAC in
the nucleus has any prognostic value for the evaluation of melanoma,
and this is the focus of active research. Furthermore, it is imperative to
determine the normal function of sAC in different microdomains in be-
nign cells and cancers such asmelanoma to determine if sAC represents
a novel therapeutic target.
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